Casodex

Bicalutamid

Method of action: Antiandrogenic, Antitumour, Endocrine Therapy

Treatment option: Prostatectomy, Cancer, Cancer,Prostate

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Casodex

Property	Description
Active ingredient	Bicalutamide
Form	Oral tablet
Pharmacological class	Non-steroidal Anti-androgen (NSAA)
General purpose	To block male hormone signals (androgens)
Origin	Synthetic compound

What Type of Medicine is Casodex and its Classification?

Casodex is a brand name for a prescription-only medicine containing the active ingredient Bicalutamide, which is classified as a non-steroidal anti-androgen (NSAA). This compound is an orally administered tablet used as a systemic therapeutic agent. The classification as an anti-androgen defines its central function: to interrupt the biological effects of natural male hormones, primarily testosterone, in the body. Bicalutamide is a synthetic compound, making it chemically distinct from natural steroid hormones.

Composition and Fundamental Mechanism of Bicalutamide

The medicine’s function is driven by the Bicalutamide molecule. This single-active ingredient formulation achieves its high-level mechanism through competitive inhibition by acting as an androgen receptor antagonist. This mechanism involves the molecule physically binding to the androgen receptors located on cells. Casodex occupies these receptor sites to inhibit the action of androgens, thereby preventing natural androgens from attaching and transmitting their growth-promoting cellular signals.

General Purpose of this Anti-Androgen Therapy

The general purpose of Casodex is to suppress cellular signals that are stimulated or sustained by the presence of androgens in the adult male patient. This specific approach, known as hormone signal blocking, utilizes Bicalutamide’s antagonism to interrupt the androgen-dependent pathways. This interruption forms the basis of its therapeutic objective: to gain control over cellular proliferation and activity that relies on the stimulatory influence of androgens, which is a key component of strategies commonly termed Androgen Deprivation Therapy (ADT).

What side effects are possible with Casodex?

Possible Side Effects and Safety Information

The safety profile of bicalutamide (Casodex) is formally documented by regulatory authorities, classifying possible adverse reactions by the frequency observed in clinical data. This classification adheres to System-Organ-Class (SOC) groupings, detailing effects on various physiological systems.

Frequency Classification of Adverse Reactions

Classification	Key Documented Adverse Reactions (Examples)	System-Organ Class (SOC)
Very Common (ge 1/10)	Hot flush, Gynaecomastia and breast tenderness, Asthenia, Peripheral oedema	Vascular, Reproductive, General disorders
Common (ge 1/100 to <1/10)	Myocardial infarction, Cardiac failure, Hepatotoxicity, Jaundice	Cardiac disorders, Hepatobiliary disorders
Uncommon (ge 1/1,000 to le 1/100)	Interstitial lung disease, Hypersensitivity reactions	Respiratory, Immune system
Rare (ge 1/10,000 to le 1/1,000)	Hepatic failure	Hepatobiliary disorders

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources include hepatic failure and interstitial lung disease, both of which have been associated with reported fatal outcomes. Cardiac events, such as myocardial infarction and cardiac failure, are also documented as Common risks. Time-related safety patterns indicate that the majority of significant hepatic changes typically occur within the first six months of beginning treatment.

Bicalutamide is contraindicated in females and children. Caution is advised when used in individuals with moderate to severe hepatic impairment. The anti-androgen effect may lead to subfertility or infertility in men. The official safety information also notes the potential to potentiate the effect of coumarin anticoagulants, which can increase bleeding risk.

Overdose and Emergency Response

Official regulatory documentation concerning Casodex (Bicalutamide) overdose management is based on established supportive procedures rather than specifically defined acute toxic manifestations. The regulatory profile provides explicit instructions regarding management limitations and the actions required when an overdose is suspected.

When to Seek Immediate Medical Help

Any suspected overdose event, regardless of the observed effects, requires that you seek immediate medical attention to begin symptomatic and supportive care as mandated by official health authorities.

Documented Overdose Profile

Category	Official Regulatory Statement
Manifestations	A single dose that results in life-threatening symptoms has not been established in regulatory documents.
Antidote	There is no specific antidote available for Bicalutamide overdose.
Management	Treatment must be symptomatic and focused on general supportive care.
Monitoring	Frequent monitoring of vital signs is required during the observation period.
Intervention	Vomiting may be induced only if the patient is observed to be alert.
Limitations	Dialysis is not likely to be helpful because the drug is highly protein bound and extensively metabolized.

This regulatory guidance emphasizes the need for immediate medical evaluation due to the documented absence of a specific antidote and the necessity of managing symptoms as they arise under continuous observation. Official documentation further advises that clinical management must consider the possibility that a patient may have taken multiple drugs concurrently.

Therapeutic Uses of Casodex

This medication is commonly used to help with managing the effects of prostate cancer, applied across domains where additional symptomatic support is needed.

Controlling Advanced Disease and Symptoms

Casodex is considered relevant for conditions characterized by periods of heightened symptoms related to advanced and metastatic disease, as well as locally advanced prostate cancer and recurrent manifestations. The therapy plays a role in managing the effects of malignancy, which contributes to easing the overall symptom load associated with systemic discomfort. This approach is relevant in contexts involving heightened systemic burden.

“The primary benefit is in supporting relief in the context of the condition.”

Managing Symptoms in Clinical Scenarios

The medicine is also utilized in specific clinical contexts, such as a short-term intervention when initiating LHRH agonist therapy. This use is applied in addressing symptoms that become more disruptive during flare-ups, offering symptomatic relief that helps patients cope more steadily with the temporary physiological imbalance of initiating treatment. It assists with maintaining functional stability during these symptomatic periods.

Quick Fact: Relief for Hormone-Driven Symptoms
Casodex is commonly used to help with symptoms related to systemic imbalance and is used in areas where short-term symptom management is appropriate.

Eligibility and Restrictions for Use

Official Eligibility Rules for Casodex (Bicalutamide)

Casodex is a prescription medicine whose use is strictly governed by regulatory classifications detailing the patient populations that are permitted, restricted, or prohibited from receiving the drug.

Category	Official Regulatory Status
Populations for whom use is allowed	Adult Males are the exclusively approved population, including older adults (geriatric patients) [Source 1.2].
Populations for whom use is contraindicated	Females, children and adolescents, and patients with a known hypersensitivity to bicalutamide or any component of the tablet are strictly prohibited from use [Source 1.2].
Pregnancy and lactation eligibility	Contraindicated in pregnant women and nursing mothers, as the medicine is not indicated for the female population [Source 1.2].
Age-related eligibility rules	Use in children and adolescents is contraindicated; safety and efficacy are not established in the pediatric population [Source 1.2]. No specific dosage adjustment is necessary for older adult males [Source 1.2].
Condition-specific eligibility rules	Use should be with caution in patients with moderate to severe hepatic impairment (liver dysfunction) due to the potential for drug accumulation [Source 1.2]. For renal impairment (kidney dysfunction), no dosage adjustment is necessary [Source 1.2].

Resulting Eligibility Structure

Official eligibility statements:

Casodex is contraindicated in females, including those who are or may become pregnant [Source 1.2].
The medicine is contraindicated for use in children; safety and efficacy have not been established in the pediatric population [Source 1.2].
Use should be exercised with caution in patients who have moderate to severe hepatic impairment [Source 1.2].
Patients with known hypersensitivity to the active substance or excipients must not use the medicine [Source 1.2].

Connection to the overall eligibility profile: Regulatory documents strictly define the eligibility profile of Casodex, limiting its use to adult males and establishing absolute prohibitions (contraindications) for the female sex, the pediatric population, and individuals with a history of hypersensitivity. Furthermore, the profile mandates special consideration for patients presenting with moderate to severe hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions of bicalutamide (Casodex) documented in official regulatory prescribing information.

Contraindicated Combinations

Co-administration is officially contraindicated with terfenadine, astemizole, and cisapride. This restriction is based on the documented potential for the active form of bicalutamide to inhibit the metabolic enzyme CYP3A4, which significantly increases the exposure of these specific medicines and carries a high risk of adverse outcomes.

Pharmacokinetic Interactions

Bicalutamide is officially documented as an inhibitor of CYP3A4. This pharmacokinetic mechanism requires caution when co-administering with other medicinal products predominantly metabolized by this enzyme, particularly those with a narrow therapeutic index. For example, clinical studies demonstrate that co-administration with midazolam (a CYP3A4 substrate) increased the drug's exposure (AUC) by up to 80% and its Cmax by 1.5-fold. No timing separation rules for administration with food or other drugs are specified in official labeling.

Anticoagulant and Pharmacodynamic Interactions

Bicalutamide has been reported to potentiate the effects of coumarin anticoagulants, such as warfarin, by displacing them from protein binding sites. This interaction can result in an increase in Prothrombin Time (PT) and International Normalized Ratio (INR), which requires close monitoring and potential dose adjustment of the anticoagulant. Official labeling also advises caution when co-administered with LHRH analogues, as the combined hormonal therapy is associated with a reduction in glucose tolerance. Caution is also advised when co-administering with medicines known to prolong the QT interval, as androgen deprivation therapy itself may carry a risk of QT prolongation.

Population-Specific Considerations

Caution is advised in patients with moderate-to-severe hepatic impairment, as data suggests the elimination of the active enantiomer of bicalutamide may be slower in this population, potentially leading to increased drug accumulation.

Mechanism of Action

How Casodex Works: The Mechanism of Action

The mechanism of action for Casodex (Bicalutamide) is centered on directly interfering with the body's androgen signaling system to limit cellular activity driven by androgen signaling.

Targeting the Androgen Receptor (AR) as a Competitive Antagonist

The drug acts as a competitive antagonist, engaging the Androgen Receptor (AR), the intracellular protein to which male hormones like Testosterone and Dihydrotestosterone (DHT) normally bind. By occupying the AR binding site, Bicalutamide physically prevents these natural androgens from attaching and activating the receptor, thereby preventing the androgen signal from initiating cellular processes. This is the first step in the mechanistic cascade.

Inhibition of Gene Transcription and Signaling

The binding of Bicalutamide renders the Androgen Receptor inactive. This inactive complex is then unable to travel to the cell nucleus to initiate the gene transcription process required to support cellular growth and proliferation. The physiological consequence of this is the systemic limitation of androgen-driven signaling in target tissues.

Modulation of the Endocrine Feedback Loop

The widespread blockade of peripheral Androgen Receptors inadvertently reduces the typical negative feedback signal to the brain’s hormone-regulating center (HPG axis). This causes a compensatory release of Luteinizing Hormone, which leads to a temporary increase in circulating testosterone. Despite this hormonal rise, the drug’s competitive antagonism maintains the receptor blockade, which renders the elevated androgens inactive at the cellular level.

Dosage and Administration Information

How to Use Casodex

The usage of Casodex (bicalutamide) is defined by standardized parameters regarding the administration route, dose, frequency, and relationship to other therapies. The medicine is provided as a film-coated tablet intended for oral use.

Official Dosing and Administration Patterns

Casodex is taken once daily at the same time each day, with the administration time being consistent whether taken in the morning or evening. The tablet can be consumed with or without food and should be swallowed whole.

There are two primary dosing regimens, which vary based on the specific context of use:

50 mg once daily: This dose is used in combination with a LHRH analog (a luteinizing hormone-releasing hormone analog) or following surgical castration.
150 mg once daily: This higher dose is used in certain regions for monotherapy or locally advanced disease.

Procedural Instructions and Course Timing

The start of Casodex therapy is procedurally linked to the partner hormonal intervention. The direction is to begin taking the tablet at the same time as the initiation of LHRH analog therapy. In some contexts, the medicine is started at least three days prior to the LHRH analog. Treatment often continues for a long-term or continuous course until specific clinical endpoints are reached.

If a dose is missed, the next scheduled dose should be taken at its regular time; the dose should not be doubled to compensate for the skipped one. Furthermore, no dosage adjustment is necessary for older patients or those with renal impairment or mild to moderate hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Casodex

The research base for Casodex (bicalutamide) is derived from evidence in controlled clinical trials, including large, international Randomized Controlled Trials (RCTs), comparative studies, and long-term follow-up analyses. This research explored the medicine's role when studied alongside, or compared with, other standard hormonal treatments for prostate carcinoma.

Evidence for Advanced (Metastatic) Prostate Carcinoma

Research has explored the use of Casodex in adult males diagnosed with advanced, metastatic disease (Stage D2). The primary evidence base for this use comes from Phase III comparative trials that evaluated Casodex administration in combination with another type of hormonal agent, specifically a Luteinizing Hormone-Releasing Hormone (LHRH) analog, or surgical castration.

Researchers note that these studies employed RCT designs to monitor how patient outcomes evolved over defined time intervals. Investigators monitored outcomes related to disease activity, such as Overall Survival (OS) and Time to Treatment Failure. Findings describe patterns related to survival and measurements of objective tumor response when Casodex was co-administered with an LHRH agonist.

Furthermore, some research contexts explored the short-term use of Casodex when LHRH agonist therapy was first initiated. This approach was studied to observe patterns related to the symptomatic flare that can occur during the initial phase of LHRH treatment. These studies contributed to understanding how symptoms evolved during defined time intervals.

Evidence for Locally Advanced Prostate Cancer (Adjuvant Use)

The primary evidence base for Casodex in non-metastatic locally advanced disease comes from large, international, long-term, double-blind, placebo-controlled trials, notably the Early Prostate Cancer (EPC) program. This research studied adult males with T3–T4 stage disease who were receiving standard local care, such as radiotherapy or radical prostatectomy.

Studies monitored long-term endpoints, including Objective Progression-Free Survival (PFS) and Overall Survival (OS). For patients with locally advanced disease, findings describe patterns related to the duration of time before the disease progressed clinically. Patterns observed in the trials were described as most evident in the group of patients who received Casodex along with radiotherapy.

What is Still Uncertain About the Casodex Evidence Base

Research continues to provide context and insight, but the available evidence base includes acknowledged limitations and gaps. Key uncertainty relates to the mixed findings observed in the localized, low-risk prostate cancer patient group, particularly concerning Overall Survival. Additionally, while the initial trials established the role of Casodex, research today is shifting toward newer-generation anti-androgen agents. Casodex is often used as a comparator drug in contemporary trials, meaning direct comparative evidence against the most modern standards of care is still emerging.

Frequently Asked Questions (FAQ)

Common questions about Casodex (FAQ)

Q: Is Casodex considered a type of chemotherapy?

A: Casodex is classified as a non-steroidal anti-androgen and works by blocking receptors that male hormones (androgens) bind to. It is a form of hormone signal blocking therapy and is generally distinguished from standard cytotoxic chemotherapy.

Q: Is it true that Casodex can cause birth defects if the father is taking it?

A: Official information indicates that bicalutamide has the potential to cause harm to a fetus. Men with female partners who are pregnant or capable of becoming pregnant should discuss the need for effective contraception with a healthcare provider, as indicated by official guidance.

Q: Can men who take Casodex still have children in the future?

A: Studies indicate that the anti-androgen effect of Casodex may lead to subfertility or infertility in men. While this effect is sometimes reversible after stopping treatment, the possibility of permanent infertility has been noted in official warnings.

Q: How quickly does Casodex leave the body after the last dose is taken?

A: The half-life of the active component of Casodex (bicalutamide) is approximately one week. This means the substance has a prolonged presence in the body after the final dose.

Q: Why is Casodex often taken together with an LHRH agonist (like Lupron or Eligard)?

A: Casodex is typically used in combination with an LHRH analog (like Lupron or Eligard) to achieve comprehensive hormonal blockade. This combined approach is designed to both stop the body from producing testosterone and block the activity of any circulating testosterone at the cellular receptor level.

Q: What does Casodex do to prevent the testosterone flare that can happen with LHRH injections?

A: When LHRH analog treatment begins, it can temporarily cause a surge of testosterone, leading to a temporary worsening of symptoms called a flare phenomenon. Casodex is started at the same time as the LHRH analog injection and is intended to manage the transient effects of this initial testosterone surge.

Q: Is it a problem if I continue taking Casodex after the initial period with the LHRH shot?

A: Casodex is generally prescribed for a long-term or continuous course alongside the LHRH analog therapy. Official regulatory instructions define its use as ongoing and continuous until certain clinical endpoints are met.

Q: Why are regular blood tests necessary while taking Casodex?

A: Official information requires regular blood testing primarily because Casodex has been associated with changes in liver function, including rare cases of severe hepatic failure. Monitoring is also necessary to check blood glucose levels and, if you take certain blood thinners, to check for potential bleeding risk.

Q: What are the most common side effects of taking Casodex for prostate cancer?

A: According to official regulatory data from clinical trials, the most common side effects (very common, or affecting more than 1 in 10 men) include hot flashes, gynecomastia (breast swelling or tenderness), weakness (asthenia), and swelling (peripheral edema).

Q: Is a change in my libido or sexual function expected with Casodex treatment?

A: Changes in sexual function are common with this type of hormonal therapy. Regulatory documents report that decreased libido (loss of sexual desire) and erectile dysfunction are common side effects observed in clinical trials.

Q: Is gynecomastia (breast swelling or tenderness) a common side effect of Casodex?

A: Yes, gynecomastia and breast tenderness are reported as very common side effects in clinical trials, affecting more than 1 in 10 men. This is a recognized effect of blocking androgens in the body.

Q: Does Casodex cause fatigue or weakness, and how can that be managed?

A: A feeling of weakness or lack of energy (asthenia) is reported as a very common side effect, affecting more than 1 in 10 men. The official product information identifies this risk, but does not provide specific management recommendations.

Q: Can Casodex affect my blood sugar levels or increase the risk of diabetes?

A: A decrease in glucose tolerance has been observed in men who are receiving Casodex in combination with an LHRH analog. For this reason, official safety information indicates that blood glucose monitoring is necessary when Casodex is taken in combination with an LHRH analog.

Q: Is there a concern about bone thinning (osteoporosis) with long-term use of Casodex?

A: Androgen deprivation therapies are known to potentially lead to effects on the skeleton. While not listed as a very common side effect of Casodex specifically, the overall class of hormonal therapy carries a risk for decreased bone mineral density over time.

Q: Does Casodex cause hair loss or changes in body hair?

A: Changes to hair growth are listed in the official side effect profile. Regulatory documents report that hair loss (alopecia) and, conversely, an increase in body hair (hirsutism) are common side effects.

Q: Can Casodex cause mood changes or depression?

A: While not listed as a very common side effect, some patient-focused drug information related to hormonal therapy reports mood changes, including feeling low or depressed. Any persistent changes in mood are generally noted in patient safety information and should be discussed with a healthcare provider.

Q: Is it normal to experience hot flashes while on Casodex?

A: Yes, experiencing hot flashes (or hot flushes) is normal and is reported as a very common side effect in clinical trials, affecting more than 1 in 10 men. It is one of the most frequently reported side effects of hormonal therapy.

Q: What precautions should I take regarding sun exposure while on Casodex?

A: Official safety information suggests avoiding direct exposure to excessive sunlight or UV light, and taking protective measures, due to reported photosensitivity (increased skin sensitivity to light).

Q: Is there a concern about Casodex causing lung problems?

A: Yes, official safety information documents that Interstitial Lung Disease (ILD) has been reported as an uncommon adverse reaction associated with Casodex. ILD is a serious condition that has been linked to fatal outcomes.

Q: Does taking Casodex affect the results of a PSA test?

A: Yes, taking Casodex is expected to affect PSA (Prostate-Specific Antigen) test results. By blocking the androgen signals, the medicine typically causes a decrease in PSA levels. Clinical studies use changes in PSA levels to monitor the treatment's effectiveness.

Q: Does Casodex cause weight gain or fluid retention?

A: Official information reports that both are possible effects. Fluid retention (peripheral edema) is reported as a very common side effect, and weight gain is also listed as a common side effect in clinical studies.

Q: Is it normal to have constipation or diarrhea while taking Casodex?

A: Yes, both constipation and diarrhea are listed in the official adverse reactions. They are reported as common side effects of the medicine.

Q: Can Casodex affect my energy levels for physical activity or exercise?

A: A feeling of weakness or lack of energy (asthenia) is reported as a very common side effect of the medicine. This may affect energy levels for physical activities or exercise.

Q: What should be done if I experience unexplained bruising or bleeding on Casodex?

A: Unexplained bruising or bleeding is noted in official warnings and should be brought to the attention of a healthcare professional promptly. This is important, particularly for patients on certain blood thinners, due to the increased risk of bleeding with Casodex.

Q: Is it common to feel a sense of uneasiness or dread while on Casodex?

A: Some patient-focused drug information reports a feeling of uneasiness or dread with bicalutamide. If you experience persistent or concerning changes to your mental state, seeking guidance from a healthcare provider is generally recommended.

Q: Does Casodex affect the body's cholesterol levels?

A: Yes, regulatory documents indicate that Casodex may affect cholesterol levels. Hypercholesterolemia (high cholesterol) is reported as a common side effect in some clinical studies.

Q: Why is Casodex generally not recommended for men with early stage prostate cancer on watchful waiting?

A: According to some regulatory guidelines, Casodex is contraindicated for patients with localized prostate cancer who are otherwise undergoing watchful waiting. This determination is based on the outcomes observed in clinical trials for this specific patient group.

Q: Can Casodex cause changes in my sleep patterns?

A: Difficulty sleeping is reported in patient information sources related to bicalutamide. If persistent changes in sleep patterns occur, official safety practice suggests consulting a healthcare professional.

Q: Is it true that Casodex is not FDA approved for use in women (such as in HRT)?

A: Yes, this is true. Casodex is contraindicated in all females and the official label states that it has no indication (approved use) for women. Its use is strictly limited to adult males.

Q: What steps should be taken if Casodex is causing severe abdominal pain?

A: Severe abdominal pain should be brought to the attention of a healthcare professional promptly, as it can be a sign of a serious liver issue such as hepatitis or hepatic failure, which requires urgent medical assessment.

Q: Can Casodex make me feel dizzy or affect my driving ability?

A: The medication may cause drowsiness or dizziness. Official patient counseling information suggests using caution when driving or operating machinery until the patient is aware of how Casodex affects them.

Q: Is it possible for Casodex to stop working after a period of time?

A: Clinical studies recognize the possibility that the medicine's effectiveness may decrease over time. Investigators monitor for an event called 'Time to Treatment Failure,' which tracks the duration of time until the medicine is no longer able to control the disease.

How should Casodex be stored and disposed of?

Casodex (bicalutamide) must be stored and disposed of according to specific regulatory requirements to maintain product integrity and ensure environmental safety.

Storage Conditions

Casodex tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in the original container, tightly closed, and protected from both excess heat and moisture and direct light. For safety, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Casodex should not be disposed of via wastewater or household trash. Official guidelines require patients to consult a pharmacist for instructions on proper disposal, which must be carried out according to local, state, and national regulations to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.